Risk Factors for New Neurologic Diagnoses in Hospitalized Patients With COVID-19 A Case-Control Study in New York City
Authors:
- Kiran T. ThakurKTKiran T. Thakur
- Victoria T. ChuVCVictoria T. Chu
- Christine HughesCHChristine Hughes
- Carla Y. KimCKCarla Y. Kim
- Shannon Fleck-DerderianSFShannon Fleck-Derderian
- Catherine E. BarrettCBCatherine E. Barrett
- Elizabeth MatthewsEMElizabeth Matthews
- Alanna BalbiABAlanna Balbi
- Amanda BilskiABAmanda Bilski
- Mashina ChombaMCMashina Chomba
- Ori LiebermanOLOri Lieberman
- Samuel D. JacobsonSJSamuel D. Jacobson
- 1 June 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 12 (4) , E66-E74
Abstract
Background and Objectives There have been numerous reports of neurologic manifestations identified in hospitalized patients infected with SARS-CoV-2, the virus that causes COVID-19. Here, we identify the spectrum of associated neurologic symptoms and diagnoses, define the time course of their development, and examine readmission rates and mortality risk posthospitalization in a multiethnic urban cohort. Methods We identify the occurrence of new neurologic diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in New York City. A retrospective cohort study was performed on 532 cases (hospitalized patients with new neurologic diagnoses within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020, and August 31, 2020). We compare demographic and clinical features of the 532 cases with 532 controls (hospitalized COVID-19 patients without neurologic diagnoses) in a case-control study with one-to-one matching and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only analysis. Results Among the 532 cases, the most common new neurologic diagnoses included encephalopathy (478, 89.8%), stroke (66, 12.4%), and seizures (38, 7.1%). In the case-control study, cases were more likely than controls to be male (58.6% vs 52.8%, p = 0.05), had baseline neurologic comorbidities (36.3% vs 13.0%, p < 0.0001), and were to be treated in an intensive care unit (62.0% vs 9.6%, p < 0.0001). Of the 394 (74.1%) cases who survived acute hospitalization, more than half (220 of 394, 55.8%) were readmitted within 6 months, with a mortality rate of 23.2% during readmission. Discussion Hospitalized patients with SARS-CoV-2 and new neurologic diagnoses have significant morbidity and mortality postdischarge. Further research is needed to define the effect of neurologic diagnoses during acute hospitalization on longitudinal post-COVID-19-related symptoms including neurocognitive impairment.Keywords
This publication has 24 references indexed in Scilit:
- Neuropathology of patients with COVID-19 in Germany: a post-mortem case seriesThe Lancet Neurology, 2020
- Neurological Predictors of Clinical Outcomes in Hospitalized Patients With COVID-19Frontiers in Neurology, 2020
- A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York CityNeurology, 2020
- Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patientsAnnals of Clinical and Translational Neurology, 2020
- Invited Review: The spectrum of neuropathology in COVID‐19Neuropathology and Applied Neurobiology, 2020
- Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, ChinaStroke, 2020
- SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 EncephalitisBrain, Behavior, and Immunity, 2020
- Defining causality in COVID-19 and neurological disordersJournal of Neurology, Neurosurgery & Psychiatry, 2020
- Sepsis-associated encephalopathyNature Reviews Neurology, 2012
- Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the Vaccine Adverse Event Reporting SystemJournal of Clinical Epidemiology, 2002